Late Onset of Organizing Pneumonia Following SARS-CoV-2 Infection: A Case Report of Successful Management and Review Literature.

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL Clinical Medicine Insights. Case Reports Pub Date : 2023-01-01 DOI:10.1177/11795476231152166
Dung Tien Le, Vu Hoang Vu, Dinh Hoang Nguyen, Duc Tan Vo, Quang Dang Duy Pham, Khang Duong Nguyen, Binh Quang Truong
{"title":"Late Onset of Organizing Pneumonia Following SARS-CoV-2 Infection: A Case Report of Successful Management and Review Literature.","authors":"Dung Tien Le,&nbsp;Vu Hoang Vu,&nbsp;Dinh Hoang Nguyen,&nbsp;Duc Tan Vo,&nbsp;Quang Dang Duy Pham,&nbsp;Khang Duong Nguyen,&nbsp;Binh Quang Truong","doi":"10.1177/11795476231152166","DOIUrl":null,"url":null,"abstract":"<p><p>A late consequence of COVID-19, organizing pneumonia is characterized by significant imaging and pathological abnormalities. The goals of this study are to better understand these abnormalities. The use of corticoid continues to be the recommended course of treatment for COVID-19. On the other hand, it is not clear whether or not corticoid has the same impact on organizing pneumonia after COVID-19. A 53-year-old male patient was identified with organized pneumonia following COVID-19 infection. He was diagnosed after experiencing severe respiratory symptoms several days with no improvement. We initiated a high dose of corticoid based on imaging and pathological findings and observed a significant response. In addition, we looked into the research that has been done concerning the diagnosis and treatment of this peculiar ailment. Patients who have been diagnosed with pneumonia after COVID 19 are required to undergo a reevaluation that includes a chest CT scan, and some of these patients may be candidates for an early lung biopsy. The most effective and convincing therapy for COVID-19-induced organizing pneumonia is corticoid treatment at a dose equivalent to 0.5 mg/kg/day of prednisone.</p>","PeriodicalId":10357,"journal":{"name":"Clinical Medicine Insights. Case Reports","volume":"16 ","pages":"11795476231152166"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/7b/10.1177_11795476231152166.PMC9884631.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795476231152166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

A late consequence of COVID-19, organizing pneumonia is characterized by significant imaging and pathological abnormalities. The goals of this study are to better understand these abnormalities. The use of corticoid continues to be the recommended course of treatment for COVID-19. On the other hand, it is not clear whether or not corticoid has the same impact on organizing pneumonia after COVID-19. A 53-year-old male patient was identified with organized pneumonia following COVID-19 infection. He was diagnosed after experiencing severe respiratory symptoms several days with no improvement. We initiated a high dose of corticoid based on imaging and pathological findings and observed a significant response. In addition, we looked into the research that has been done concerning the diagnosis and treatment of this peculiar ailment. Patients who have been diagnosed with pneumonia after COVID 19 are required to undergo a reevaluation that includes a chest CT scan, and some of these patients may be candidates for an early lung biopsy. The most effective and convincing therapy for COVID-19-induced organizing pneumonia is corticoid treatment at a dose equivalent to 0.5 mg/kg/day of prednisone.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SARS-CoV-2感染后迟发性肺炎一例成功处理及文献综述
作为COVID-19的晚期后果,组织性肺炎的特征是明显的影像学和病理异常。本研究的目的是为了更好地了解这些异常。使用皮质激素仍然是COVID-19的推荐治疗方案。另一方面,尚不清楚皮质激素是否对COVID-19后组织肺炎具有相同的影响。一名53岁男性患者在COVID-19感染后被确诊为有组织肺炎。他在出现严重的呼吸道症状数天后被诊断出来,但没有任何改善。根据影像学和病理结果,我们开始使用高剂量的皮质激素,并观察到明显的反应。此外,我们还研究了有关这种特殊疾病的诊断和治疗的研究。COVID - 19后被诊断为肺炎的患者需要进行重新评估,包括胸部CT扫描,其中一些患者可能需要进行早期肺活检。对于covid -19诱导的组织性肺炎,最有效和最令人信服的治疗方法是皮质激素治疗,剂量相当于0.5 mg/kg/天的强的松。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Medicine Insights. Case Reports
Clinical Medicine Insights. Case Reports MEDICINE, GENERAL & INTERNAL-
CiteScore
1.10
自引率
0.00%
发文量
57
审稿时长
8 weeks
期刊最新文献
Intra-Parotid Recurrent Nasopharyngeal Carcinoma Following Intensity-Modulated Radiation Therapy: A Case Report. Delayed Diagnosis of Constrictive Pericarditis Resulting in Recurrent Heart Failure: A Case Report. Electrocoagulation Therapy for Urethral Condyloma Acuminata in a Male Patient: Case Report. Giant Cell Tumor of the Synovial Pod of the Third Toe on the Right Foot: Report of a Case. Thinking Induced by Acute Kidney Injury of Diquat Poisoning: Cases Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1